The company described the product as “the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia.”
“The FDA approval of Abiliti Overnight marks an important milestone in our commitment to help change the trajectory of eye health and reshape the future of children with myopia,” said Xiao-Yu Song, MD, PhD, global head of research and development, Johnson & Johnson Vision. “We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with Abiliti Overnight Therapeutic Lenses, and continuing with additional products and services to address the progression of myopia.”
The lenses are expected to be available in the U.S. by the end of this year.
